Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

European Commission. Europe’s beating cancer plan: communication form the commission to the European Parliament and the Council. 2022. https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf.

Belgian Cancer Registry. Data module. https://kankerregister.org/fr/module-de-donn%C3%A9es.

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global cancer observatory: cancer today GLOBOCAN 2022. Europe. https://gco.iarc.who.int/today. Accessed 17 Sept 2024.

Brussel Times. Number of cancer cases in Belgium highest in a decade. 2024. https://www.brusselstimes.com/1141585/number-of-cancer-cases-in-belgium-highest-in-a-decade.

Wojtyla C, Bertuccio P, Wojtyla A, La Vecchia C. European trends in breast cancer mortality, 1980–2017 and predictions to 2025. Eur J Cancer. 2021. https://doi.org/10.1016/j.ejca.2021.04.026.

Article  PubMed  Google Scholar 

Federal Agency for Medicines and Health Products. Authorization of pembrolizumab for use in Belgium. 2017. https://medicinesdatabase.be/human-use/medicines/62bc233c8ab5583c188d7ab5?search=%7B%22term%22:%22pembrolizumab%22%7D.

European Medicines Agency. Keytruda. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda#authorisation-details.

Nieuwsblad. New cancer therapy will help 22,000 people in the next five years. [Article in Dutch]. 2017. https://www.nieuwsblad.be/cnt/dmf20180617_03566829#:~:text=Zo%E2%80%99n%204.500%20pati%C3%ABnten%20zijn%20de%20voorbije%20twee%20jaar%20behandeld.

Rachev B, Wilking N, Kobelt G, Spandonaro F, Rajer M, Roediger A, et al. Budget projections and clinical impact of an immuno-oncology class of treatments: experience in four EU markets. J Cancer Policy. 2021. https://doi.org/10.1016/j.jcpo.2021.100279.

Article  PubMed  Google Scholar 

Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021. https://doi.org/10.7150/jca.57334.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.562315.

Article  PubMed  PubMed Central  Google Scholar 

Yang T, Li W, Huang T, Zhou J. Immunotherapy targeting PD-1/PD-L1 in early-stage triple-negative breast cancer. J Pers Med. 2023. https://doi.org/10.3390/jpm13030526.

Article  PubMed  PubMed Central  Google Scholar 

Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, et al. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. Eur J Cancer. 2021. https://doi.org/10.1016/j.ejca.2021.08.028.

Article  PubMed  PubMed Central  Google Scholar 

Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024. https://doi.org/10.1016/S0140-6736(24)01756-2.

Article  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2409932.

Article  PubMed  Google Scholar 

Luke JJ, Ascierto PA, Khattak MA, de la Cruz ML, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol. 2024. https://doi.org/10.1200/JCO.23.02355.

Article  PubMed  Google Scholar 

Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. Eur J Cancer. 2024. https://doi.org/10.1016/j.ejca.2024.114327.

Article  PubMed  Google Scholar 

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2312695.

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837]. 2022. Accessed 2 Oct 2024.

National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766]. 2022. Accessed 2 Oct 2024.

National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830]. 2022. Accessed 2 Oct 2024.

National Institute for Health and Care Excellence (NICE). Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [TA851]. 2022. https://www.nice.org.uk/guidance/ta851. Accessed 4 Sept 2024.

Cleemput I, Neyt M, Van de Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012.

Google Scholar 

Statbel. Structure de la population. 2022. https://statbel.fgov.be/fr/themes/population/structure-de-la-population#news. Accessed 23 Nov 2022.

Merck & Co. Inc. Rahway, NJ, USA. Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475-054/1325-MG/KEYNOTE-054). ClinicalTrials.gov identifier: NCT02362594. https://clinicaltrials.gov/study/NCT02362594. Accessed 24 Mar 2025.

Merck & Co. Inc. Rahway, NJ, USA. Safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (MK-3475-564/KEYNOTE-564). ClinicalTrials.gov identifier: NCT03142334. https://clinicaltrials.gov/study/NCT03142334. Accessed 24 Mar 2025.

Merck & Co. Inc. Rahway, NJ, USA. Study of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants with triple negative breast cancer (TNBC) (MK-3475-522/KEYNOTE-522). ClinicalTrials.gov identifier: NCT03036488. https://clinicaltrials.gov/study/NCT03036488. Accessed 24 Mar 2025.

Merck & Co. Inc. Rahway, NJ, USA. Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma (MK-3475-716/KEYNOTE-716). ClinicalTrials.gov identifier: NCT03553836. https://www.clinicaltrials.gov/study/NCT03553836. Accessed 28 Aug 2024.

European Society of Medical Oncology (ESMO). ESMO clinical practice guidelines. https://www.esmo.org/guidelines/guidelines-by-topic. Accessed 2024.

Institut national d’assurance maladie invalidité (INAMI). Médicaments et produits radio-pharmaceutiques remboursables par l’assurance soins de santé. https://webappsa.riziv-inami.fgov.be/ssp/ProductSearch. Accessed 2024.

European Medicines Agency. KEYTRUDA: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Accessed 18 May 2022.

European Medicines Agency. OPDIVO: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Accessed 19 May 2022.

Li X, Wang J, Yao Y, Yang L, Li Z, Yu C, et al. Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.18906.

Article  PubMed  PubMed Central  Google Scholar 

Huang M, Fasching AP, Haiderali A, Xue W, Yang C, Pan W, et al. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab for high-risk early-stage triple-negative breast cancer in the United States. Adv Ther. 2023. https://doi.org/10.1007/s12325-022-02365-1.

Article  PubMed  PubMed Central  Google Scholar 

Favre-Bulle A, Bencina G, Zhang S, Jiang R, Andritschke D, Bhadhuri A. Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. J Med Econ. 2023. https://doi.org/10.1080/13696998.2023.2174748.

Article  PubMed  Google Scholar 

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.4500.

Article  Google Scholar 

Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, et al. A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. Eur Urol. 2021. https://doi.org/10.1016/j.eururo.2021.03.016.

Article  PubMed  Google Scholar 

National Cancer Institute. SEER-medicare linked data resource. https://healthcaredelivery.cancer.gov/seermedicare/.

Merck & Co. Inc. Rahway NJ USA. Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426/KEYNOTE-426). ClinicalTrials.gov identifier: NCT02853331. https://clinicaltrials.gov/study/NCT02853331. Accessed 24 Mar 2025.

Merck & Co. Inc. Rahway NJ USA. Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab in participants with advanced melanoma (MK-3475-006/KEYNOTE-006). ClinicalTrials.gov identifier: NCT01866319. https://clinicaltrials.gov/study/NCT01866319. Accessed 24 Mar 2025.

Ribas A, Hodi FS, Kurland JF, Shahabi V, Francis S, Konto C, et al. CA184-161: a phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol. 2012. https://doi.org/10.1200/jco.2012.30.15_suppl.tps8603.

Article  PubMed  PubMed Central  Google Scholar 

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase i dose-escalation study. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.72.2850.

Article  PubMed  PubMed Central  Google Scholar 

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016. https://doi.org/10.1016/S1470-2045(16)30366-7.

Article  PubMed  PubMed Central  Google Scholar 

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015. https://doi.org/10.1016/S0140-6736(15)60898-4.

Article  PubMed  Google Scholar 

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1412082.

Article  PubMed  PubMed Central